DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2018 to Q4 2025

Type / Class
Equity / Voting Common Shares, no par value
Symbol
DMAC on Nasdaq
Shares outstanding
51,654,406
Price per share
$7.96
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
12,754,591
Total reported value
$82,807,935
% of total 13F portfolios
0%
Share change
+4,001,424
Value change
+$25,371,563
Number of holders
77
Price from insider filings
$7.96
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TomEnterprise AB 16% $32,695,950 8,383,577 TomEnterprise AB 23 Jul 2025
TRILL AB 15% +14% $46,586,790 +$6,000,000 7,764,465 +15% Trill AB 14 Aug 2025
JACINTO RICHARD II 9.6% $34,067,114 4,958,823 Richard Jacinto II 30 Sep 2025
COOPERMAN LEON G 6.3% +5% $22,471,432 +$1,096,446 3,269,761 +5.1% Cooperman Leon G. 30 Sep 2025

As of 30 Sep 2025, 77 institutional investors reported holding 12,754,591 shares of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC). This represents 25% of the company’s total 51,654,406 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) together control 23% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
COOPERMAN LEON G 6.3% 3,269,761 +98% 0.55% $17,644,158
BlackRock, Inc. 3.2% 1,678,139 +41% 0% $11,528,816
MILLENNIUM MANAGEMENT LLC 2.3% 1,187,309 0.01% $8,156,813
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE 1.7% 875,000 +35% 11% $6,011,250
GEODE CAPITAL MANAGEMENT, LLC 1.4% 711,818 +13% 0% $4,891,114
VANGUARD GROUP INC 1.3% 664,575 -57% 0% $4,565,630
MORGAN STANLEY 1.1% 579,585 +141% 0% $3,981,749
FIRST MANHATTAN CO. LLC. 0.98% 505,000 -17% 0.01% $3,469,350
STATE STREET CORP 0.92% 476,583 +89% 0% $3,274,125
Bleichroeder LP 0.74% 382,317 0% 0.51% $2,626,518
NORTHERN TRUST CORP 0.66% 339,578 +4.6% 0% $2,332,901
LPL Financial LLC 0.39% 203,150 +2.9% 0% $1,395,641
OSAIC HOLDINGS, INC. 0.35% 182,305 +26% 0% $1,253,699
Corient Private Wealth LLC 0.27% 140,000 0% $961,800
Corient IA LLC 0.26% 132,500 0.68% $910,275
CANTOR FITZGERALD, L. P. 0.19% 100,000 0.01% $687,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.18% 92,427 +16% 0% $634,973
GOLDMAN SACHS GROUP INC 0.15% 77,292 +332% 0% $530,996
Nuveen, LLC 0.14% 74,667 +117% 0% $512,962
CITADEL ADVISORS LLC 0.13% 69,352 0% $476,448
Blue Trust, Inc. 0.13% 69,122 0% 0.01% $474,868
Bank of New York Mellon Corp 0.13% 68,941 +15% 0% $473,621
JANE STREET GROUP, LLC 0.11% 57,546 0% $395,341
Meridian Wealth Management, LLC 0.1% 51,666 +89% 0.01% $354,945
Private Capital Management, LLC 0.1% 50,000 0.03% $343,500

Institutional Holders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 74,248 $591,014 +$1,592 $7.96 4
2025 Q3 12,754,591 $82,807,935 +$25,371,563 $6.87 77
2025 Q2 8,764,697 $34,183,334 +$4,951,594 $3.90 58
2025 Q1 7,514,092 $28,477,666 +$2,854,596 $3.79 57
2024 Q4 6,729,012 $36,539,618 +$6,248,431 $5.43 45
2024 Q3 5,580,411 $23,326,555 +$2,250,136 $4.19 40
2024 Q2 5,062,392 $14,934,296 +$1,369,212 $2.95 32
2024 Q1 4,598,019 $12,730,274 +$2,073,072 $2.77 31
2023 Q4 3,840,738 $10,907,609 -$629,214 $2.84 37
2023 Q3 4,250,465 $10,966,479 +$1,920,978 $2.58 35
2023 Q2 3,490,534 $15,080,277 +$4,150,477 $4.32 30
2023 Q1 2,565,385 $3,924,875 +$61,558 $1.53 22
2022 Q4 2,524,139 $3,989,530 -$6,541 $1.58 27
2022 Q3 2,527,104 $3,132,035 -$2,355,232 $1.24 23
2022 Q2 3,668,922 $7,411,731 -$802,498 $2.02 24
2022 Q1 4,006,054 $10,017,522 -$427,839 $2.50 28
2021 Q4 3,993,298 $14,891,858 +$4,430,787 $3.73 34
2021 Q3 2,804,345 $11,247,922 -$4,241,878 $4.01 31
2021 Q2 3,783,974 $16,902,446 -$48,644,584 $4.45 38
2021 Q1 5,694,347 $88,119,211 +$33,217,401 $9.15 38
2020 Q4 5,983,974 $60,607,941 +$30,865 $10.14 34
2020 Q3 6,707,026 $28,383,192 +$15,491,837 $4.24 30
2020 Q2 3,034,327 $21,027,519 +$1,227,002 $6.93 20
2020 Q1 2,928,881 $8,241,240 +$5,983,161 $2.80 18
2019 Q4 806,746 $3,914,130 -$398,177 $4.85 13
2019 Q3 956,852 $1,976,000 -$928,156 $2.07 14
2019 Q2 1,283,324 $6,365,000 +$1,445,583 $4.96 14
2019 Q1 1,013,152 $4,601,000 +$283,018 $4.54 10
2018 Q4 1,032,562 $3,003,000 +$3,003,000 $2.91 7